Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma

BACKGROUND: The use of opioids in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is associated with shorter survival and not dependent on the expression of the mu-opioid receptor (MOR). The role of opioid use and MOR expression in stage I-III PDAC has not been investigated. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hao, Qu, Mengdi, Gorur, Aysegul, Sun, Zhirong, Cata, Juan P., Chen, Wankun, Miao, Changhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249918/
https://www.ncbi.nlm.nih.gov/pubmed/34222012
http://dx.doi.org/10.3389/fonc.2021.686877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249918/
https://www.ncbi.nlm.nih.gov/pubmed/34222012
http://dx.doi.org/10.3389/fonc.2021.686877

Ejemplares similares